Shire expands rare disease reach with Viropharma Purchase
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged acquisition, Basingstoke, Cinryze, clinical development, EU, Flemming Ornskov, Geneva, immune disorder hereditary angioedema, Lotus Tissue Repair, marketed products, Pipeline, regulatory approval, restructure, SARcode, Shire, Shire HGT, Shire Rare Disease, Switzerland, USA, Viropharma, Zug
Leave a comment
Liftstream Attending World Orphan Drug Congress in Geneva
Authored by Karl Simpson
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged Cydan, David Mott, Duchenne Muscular Dystrophy, funding, Liftstream, NEA, Orphan drugs, Prosensa, PTC Therapeutics, public private funding, Rare Disease, Sarepta, Shire, Summit, venture capital, Viropharma, WODC, world orphan drug congress
Leave a comment
Roche Returns to Antibiotics with Polyphor Deal
Authored by James Sheppard
Posted in M&A Finance and Funding, Pharmaceutical business
Tagged A*STAR, antibiotics, AstraZeneca, bacterial infection, CDC, Center for Disease Control & Prevention, clinical development, ETC and ETPL, gRED, Head of Infectious Diseases Discovery and Translational, hospital-acquired infection, infection, Infectious Disease, John Reed, macrocycle, partnering, Polyphor, pRED, Pseudomonas aeruginosa, Roche, Singapore, Switzerland, Tom Frieden
Leave a comment
Fidelity Biosciences and REGENX launch new gene therapy company
Authored by James Sheppard
Posted in M&A Finance and Funding, Orphan Drugs and Rare Diseases, Pharmaceutical business
Tagged AAV, Allan M. Fox, Ben Auspitz, deno-associated virus, Dimension Therapeutics, Donald J. Hayden, Emil Kakkis, Fidelity Biosciences, FOXKISER, Gene therapy, genetic disease, Genzyme, hemophilia, investors, James Wilson, REGENX, Sam Wandsworth, series A funding, Thomas R. Beck, Ultragenyx, venture capital
Leave a comment
